| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $1,886,559 | 26 | 100 |
| Watkins Tim | CMO & Head of Development | 0 | $0 | 4 | $322,557 | $-322,557 |
| Stengone Carmine N. | CEO and President | 0 | $0 | 7 | $401,378 | $-401,378 |
| Lorrain Daniel S. | Chief Scientific Officer | 0 | $0 | 15 | $1.16M | $-1.16M |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and …
Over the last 12 months, insiders at Contineum Therapeutics, Inc. have bought $0 and sold $1.89M worth of Contineum Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Contineum Therapeutics, Inc. have bought $0 and sold $1M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-08 | Sale | Stengone Carmine N. | CEO and President | 2,500 0.0069% | $16.46 | $41,142 | -21.36% | |
| 2026-08-03 | Sale | Stengone Carmine N. | CEO and President | 2,500 0.0067% | $16.01 | $40,029 | -15.07% | |
| 2026-07-09 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 25 <0.0001% | $16.00 | $400 | -8.67% | |
| 2026-07-08 | Sale | Stengone Carmine N. | CEO and President | 2,500 0.0073% | $16.00 | $40,000 | -9.52% | |
| 2026-07-01 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 8,353 0.0232% | $15.84 | $132,290 | -6.63% | |
| 2026-06-30 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 28,826 0.0754% | $16.04 | $462,288 | -12.75% | |
| 2026-06-30 | Sale | Stengone Carmine N. | CEO and President | 10,000 0.0261% | $16.01 | $160,080 | -12.75% | |
| 2026-06-30 | Sale | Watkins Tim | CMO & Head of Development | 10,833 0.0283% | $16.02 | $173,590 | -12.75% | |
| 2026-06-01 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 4,170 0.0109% | $13.16 | $54,862 | +5.73% | |
| 2026-05-01 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 4,170 0.0122% | $13.12 | $54,694 | +4.47% | |
| 2026-04-06 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 4,170 0.0112% | $13.43 | $56,014 | +0.37% | |
| 2026-03-02 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 4,170 0.0112% | $15.01 | $62,585 | -12.39% | |
| 2026-03-02 | Sale | Watkins Tim | CMO & Head of Development | 3,611 0.0097% | $15.02 | $54,220 | -12.39% | |
| 2026-02-25 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 3,824 0.0106% | $16.01 | $61,228 | -14.80% | |
| 2026-02-25 | Sale | Stengone Carmine N. | CEO and President | 2,700 0.0075% | $16.02 | $43,242 | -14.80% | |
| 2026-02-24 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 4,300 0.0118% | $16.03 | $68,936 | -15.57% | |
| 2026-02-24 | Sale | Stengone Carmine N. | CEO and President | 4,400 0.0121% | $16.02 | $70,486 | -15.57% | |
| 2026-02-19 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 100 0.0003% | $16.00 | $1,600 | -15.75% | |
| 2026-02-11 | Sale | Lorrain Daniel S. | Chief Scientific Officer | 400 0.0011% | $16.00 | $6,400 | -11.34% | |
| 2026-02-11 | Sale | Stengone Carmine N. | CEO and President | 400 0.0011% | $16.00 | $6,400 | -11.34% |
| Increased Positions | 61 | +107.02% | 13M | +71.92% |
| Decreased Positions | 23 | -40.35% | 768,279 | -4.35% |
| New Positions | 32 | New | 6M | New |
| Sold Out Positions | 14 | Sold Out | 231,524 | Sold Out |
| Total Postitions | 95 | +66.67% | 30M | +67.57% |
| Ra Capital Management, L.P. | $24,170.00 | 7.07% | 2.12M | +2M | New | 2025-09-30 |
| Johnson & Johnson | $22,543.00 | 6.6% | 1.98M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $19,591.00 | 5.73% | 1.72M | 0 | 0% | 2025-09-30 |
| Franklin Resources Inc | $18,857.00 | 5.52% | 1.66M | -43,277 | -2.55% | 2025-09-30 |
| Vanguard Group Inc | $10,983.00 | 3.21% | 964,232 | +220,231 | +29.6% | 2025-09-30 |
| Balyasny Asset Management L.P. | $10,836.00 | 3.17% | 951,320 | +951,320 | New | 2025-09-30 |
| Fmr Llc | $9,281.00 | 2.72% | 814,871 | -28,279 | -3.35% | 2025-09-30 |
| Sectoral Asset Management Inc | $9,121.00 | 2.67% | 800,787 | 0 | 0% | 2025-09-30 |
| Perceptive Advisors Llc | $8,139.00 | 2.38% | 714,592 | +15,106 | +2.16% | 2025-09-30 |
| Hhlr Advisors, Ltd. | $7,624.00 | 2.23% | 669,337 | 0 | 0% | 2025-09-30 |